ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.05 · Revenue $5.40M · 1 analysts
Est. EPS $-0.08 · Revenue $3.26M · 1 analysts
Est. EPS $-0.24 · Revenue $15.14M · 1 analysts
Est. EPS $-0.06 · Revenue $3.59M · 1 analysts
EPS $0.16 · Revenue $8.07M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $27.6M | +4.3% | -30.6% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-1.0M | +51.8% | -5.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +41.4% | +38.1% | -24.6% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +6.0% | +196.4% | +41.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -3.8% | +53.8% | +36.2% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $1.2M | +1236.0% | -32.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +4.4% | +1188.7% | -3.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 48.8% | -11.1% | -9.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.26x | +24.9% | -1.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $42.5M | -5.7% | +5.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.12 vs -0.24 | +50.0% | 0.20 vs 0.05 | +300.0% |
| Revenue Surprise | $27.6M vs $15.1M | +82.6% | $7.2M vs $5.4M | +33.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 16, 2028 | te Boekhorst Paul Francis Olivier | director, officer: President and CEO | Non Qualified Stock Option (right to buy) | — | 25,329 | $5.90 |
| Jun 18, 2026 | te Boekhorst Paul Francis Olivier | director, officer: President and CEO | Common Stock, par value $.01 per share | A | 8,000 | $9.49 |
| Apr 15, 2026 | DiMarco Anthony | director | Non Qualified Stock Options (Right to buy) | — | 17,899 | $7.60 |
| Apr 15, 2026 | Guillemette Gilles | director | Non Qualified Stock Options (Right to buy) | — | 17,899 | $7.60 |
| Apr 15, 2026 | Turner Kathy V | director | Non Qualified Stock Options (Right to buy) | A | 17,899 | $7.60 |
Good morning, and welcome to the ImmuCell Corporation conference call to discuss unaudited second quarter 2026 financial results. Operator provided instructions. Please note this event is being recorded. I would now like to turn the conference over to Joe Diaz of Lytham Partners. Please go ahead.
Thank you. Good morning, and welcome. As the conference call operator indicated, my name is Joe Diaz with Lytham Partners. We are the Investor Relations consulting firm for ImmuCell. I thank all of you for joining us today to discuss the unaudited earnings for the second quarter and 6 months ended June 30, 2026. Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements, which include any statement that refers to future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today. Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results, outcomes or events is available under the cautionary note regarding forward-looking statements or the safe harbor statement provided with the press release that the company filed last night, along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Friday, August 14, 2026. The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non-GAAP financial measures may be made during today's call. With that said, let me turn the call over to Oliver Te Boekhorst, President and CEO of ImmuCell Corporation, for some opening remarks. Oliver?
Thanks, Joe, and good morning, everyone. It's my pleasure to welcome you to today's discussion of ImmuCell's results for the second quarter of 2026. Our discussion of results will be accompanied by a few slides that are also part of our updated investor presentation that you can find on our Investor page, immucell.com/investors. In late 2025, ImmuCell made significant changes to better position ourselves for success, including a strategic focus on the calf scours market and investments in leadership, sales force expansion and manufacturing. Our rationale for this shift was that we compete very effectively with First Defense, our highly differentiated calf scours preventative product in the large growing calf health market and that we believe our portfolio has considerable runway for further expansion domestically, internationally and through selected innovations. Since we introduced this focus on First Defense and enhanced our yield improvement efforts, we have accelerated our growth and increased our share. Our strong commercial results reflect the benefits of restored product …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Bobbi Jo Brockmann | Senior Vice President of Sales & Marketing | USD 425,816 | Female | 1977 | Active |
Timothy C. Fiori | CFO, Secretary & Treasurer | USD 337,280 | Male | 1979 | Active |
Paul F. Olivier Te Boekhorst | President, Chief Executive Officer & Director | USD 172,665 | Male | 1972 | Active |
John W. Zinckgraf | Director of Product Development | — | — | — | Active |
A. Gustavo Scaffa | Senior Director of Quality | — | Male | — | Active |
Elizabeth S. Toothaker | Director of Finance & Administration and Controller | — | Female | — | Active |
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
ImmuCell Corporation (NASDAQ: ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $8.64 and traded as high as $10.49. ImmuCell shares last traded at $10.06, with a volume of 11,130 shares traded. Analysts Set New Price Targets A number
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.
